Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a choline- and folate-deficient diet

Toxicology and Applied Pharmacology

Volumn 262, Issue 1, 2012, Pages 52-59

  Tryndyak, Volodymyr P ^a   Latendresse, John R ^a   Montgomery, Beverly ^a   Ross, Sharon A ^b   Beland, Frederick A ^a   Rusyn, Ivan ^c   Pogribny, Igor P ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c University of North Carolina at Chapel Hill   (United States)

Author keywords

Inter individual differences; MicroRNAs; Mouse; Nonalcoholic fatty liver disease

Indexed keywords

CHOLINE; FOLIC ACID; MICRORNA; MICRORNA 122; MICRORNA 181A; MICRORNA 192; MICRORNA 200B; MICRORNA 34A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C3H MOUSE; C57BL 6 MOUSE; CONTROLLED STUDY; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE SEVERITY; FOLIC ACID DEFICIENCY; GENETIC VARIABILITY; INJURY SEVERITY; LIVER INJURY; LIVER LEVEL; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; VITAMIN DEFICIENCY;

ANIMALS; BIOLOGICAL MARKERS; CHOLINE DEFICIENCY; DISEASE MODELS, ANIMAL; FATTY LIVER; FOLIC ACID DEFICIENCY; GENETIC PREDISPOSITION TO DISEASE; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, INBRED STRAINS; MICRORNAS; SEVERITY OF ILLNESS INDEX; SPECIES SPECIFICITY;

MUS;

EID: 84861728344     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.04.018     Document Type: Article

References (39)

1. Ariz U., Mato J.M., Lu S.C., Martines-Chantar M.L. Nonalcoholic steatohepatitis, animal models, and biomarkers: what is new?. Methods Mol. Biol. 2010, 593:109-136.
2. Aylor D.L., Valdar W., Foulds-Mathes W., Buus R.J., Verdugo R.A., Baric R.S., Ferris M.T., Frelinger J.A., Heise M., Frieman M.B., Gralinski L.E., Bell T.A., Didion J.D., Hua K., Nehrenberg D.L., Powell C.L., Steigerwalt J., Xie Y., Kelada S.N.P., Collins F.C., Yang I.V., Schwartz D.A., Branstetter L.A., Chesler E.J., Miller D.R., Spence J., Liu E.Y., McMillan L., Sarkar A., Wang J., Wang W., Zhang Q., Broman K.W., Korstanje R., Durrant C., Mott R., Iraqi F.A., Pomp D., Threadgill D., Pardo-Manuel de Villena F., Churchill G.A. Genetic analysis of complex traits in the emerging collaborative cross. Genome Res. 2011, 21:1213-1222.
3. Bellentani S., Scaqlioni F., Marino M., Begogni G. Epidemiology of non-alcoholic fatty liver disease. Dig. Dis. 2010, 28:155-161.
4. Bihrer V., Friedrich-Rust M., Kronenberger B., Forestier N., Haupenthal J., Shi Y., Peveling-Oberhag J., Radeke H.H., Sarrazin C., Herrmann E., Zeuzem S., Waidmann O., Piiper A. Serum miR-122 as biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am. J. Gastroenterol. 2011, 106:1663-1669.
5. Browning J.D., Szczepaniak L.S., Dobbins R., Nuremberg P., Horton J.D., Cohen J.C., Grundy S.M., Hobbs H.H. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
6. Cermelli S., Ruggieri A., Marrero J.A., Ioannou G.N., Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 2011, 6:e23937.
7. Chalasani N., Guo X., Loomba R., Goodarzi M.O., Haritunians T., Kwon S., Cui J., Taylor K.D., Wilson L., Cummings O.W., Chen Y.D., Rotter J.I. Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease. Gastroenterology 2010, 139:1567-1576. Nonalcoholic Steatohepatitis Clinical Research Network.
8. Cheung O., Puri P., Eicken C., Contos M.J., Mirshahi F., Maher J.W., Kellum J.M., Min H., Luketic V.A., Sanyal A.J. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 2008, 48:1810-1820.
9. Cohen J.C., Horton J.D., Hobbs H.H. Human fatty liver disease: old questions and new insights. Science 2001, 332:1519-1523.
10. Cortez M.A., Calin G.A. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin. Biol. Ther. 2009, 9:703-711.
11. Day C.P. Non-alcoholic fatty liver disease: a massive problem. Clin. Med. 2011, 11:176-178.
12. Gatti D.M., Lu L., Williams R.W., Sun W., Wright F.A., Threadgill D.W., Rusyn MicroRNA expression in the livers of inbred mice. Mutat. Res. 2011, 714:126-133.
13. Girard M., Jacquemin E., Munnich A., Lyonnet S., Henrion-Caude A. miR-122, a paradigm for the role of microRNAs in the liver. J. Hepatol. 2008, 48:648-656.
14. Hebbard L., George J. Animal models of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 2011, 8:35-44.
15. Hill-Baskin A.E., Markiewski M.M., Buchner D.A., Shao H., DeSantis D., Hsiao G., Subramaniam S., Berger N.A., Croniger C., Lambris J.D., Nadeau J.H. Diet-induced hepatocellular carcinoma in genetically predisposed mice. Hum. Mol. Genet. 2010, 18:2975-2988.
16. Larter C.Z., Yeh M.M. Animal models of NASH: getting both pathology and metabolic context right. J. Gastroenterol. Hepatol. 2008, 23:1635-1648.
17. Larter C.Z., Chitturi S., Heydet D., Farrel G.C. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J. Gastroenterol. Hepatol. 2010, 25:672-690.
18. Laterza O.F., Lim L., Garrett-Engele P.W., Vlasakova K., Muniappa N., Tanaka W.K., Johnson J.M., Sina J.F., Fare T.L., Sistare F.D., Glaab W.E. Plasma microRNAs as sensitive and specific biomarkers of tissue injury. Clin. Chem. 2009, 55:1977-1983.
19. Lewis A.P., Jopling C.L. Regulation and biological function of the liver-specific miR-122. Biochem. Soc. Trans. 2010, 38:1553-1557.
20. Maher J.J. New insights from rodent models of fatty liver disease. Antioxid. Redox Signal. 2011, 15:535-550.
21. Marra F., Gastaldelli A., Svegliati Baroni G., Tell G., Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol. Med. 2008, 14:72-81.
22. Morita K., Taketomi A., Shirabe K., Umeda K., Kayashima H., Ninomiya M., Uchiyama H., Soejima Y., Maehara Y. Clinical significance and potential of hepatic microRNA-122 expression in hepatitis C. Liver Int. 2011, 31:474-484.
23. Pais R., Pascale A., Fedchuck L., Charlotte F., Poynard T., Ratziu V. Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease. Clin. Res. Hepatol. Gastroenterol. 2011, 35:23-28.
24. Pascale A., Pais R.A., Ratziu V. An overview of nonalcoholic steatohepatitis: past, present and future directions. J. Gastrointestin. Liver Dis. 2010, 19:415-423.
25. Pogribny I.P., Tryndyak V.P., Bagnyukova T.V., Melnyk S., Montgomery B., Ross S.A., Latendresse J.R., Rusyn I., Beland F.A. Hepatic epigenetic phenotype predetermines individual susceptibility to hepatic steatosis in mice fed a lipogenic methyl-deficient diet. J. Hepatol. 2009, 51:176-186.
26. Pogribny I.P., Starlard-Davenport A., Tryndyak V.P., Han T., Ross S.A., Rusyn I., Beland F.A. Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Lab. Invest. 2010, 90:1437-1446.
27. Rusyn I., Gatti D.M., Wiltshire T., Kleeberger S.R., Threadgill D.W. Toxicogenetics: population-based testing of drug and chemical safety in mouse models. Pharmacogenomics 2010, 11:1127-1136.
28. Sanyal A.J., Brunt E.M., Kleiner D.E., Kowdley K.V., Chalasani N., Lavine J.E., Ratziu V., McCullough A. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011, 54:344-353.
29. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 2008, 3:1101-1108.
30. Schwimmer J.B., Celedon M.A., Lavine J.E., Salem R., Campbell N., Schork N.J., Shiehmorteza M., Yokoo T., Chavez A., Middleton M.S., Sirlin C.B. Heritability of nonalcoholic fatty liver disease. Gastroenterology 2011, 136:1585-1592.
31. Siegel A.B., Zhu A.X. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009, 115:5651-5661.
32. Starkey Lewis P.J., Dear J., Platt V., Simpson K.J., Craig D.G., Antoine D.J., French N.S., Dhaun N., Webb D.J., Costello E.M., Neoptolemos J.P., Moggs J., Goldring C.E., Park B.K. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 2011, 54:1767-1776.
33. Starley B.Q., Calcagno C.J., Harrison S.A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010, 51:1820-1832.
34. Tiniakos D.G., Vos M.B., Brunt E.M. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu. Rev. Pathol. 2010, 5:145-171.
35. Wang B., Majumder S., Nuovo G., Kutay H., Volinia S., Patel T., Schmittgen T.D., Croce C., Ghoshal K., Jacob S.T. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology 2009, 50:1152-1161.
36. Wang K., Zhang S., Marzolf B., Troisch P., Brightman A., Hu Z., Hood L.E., Galas D.J. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:4402-4407.
37. Welzel T.M., Graubard B.I., Zeuzem S., El-Serag H.B., Davila J.A., McGlynn K.A. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 2011, 54:463-471.
38. Yamazaki Y., Kakizaki S., Takizawa D., Ichikawa T., Sato K., Takagi H., Mori M. Interstrain differences in susceptibility to non-alcoholic steatohepatitis. J. Gastroenterol. Hepatol. 2008, 23:276-282.
39. Yang H., Wang J.R., Didion J.P., Buus R.J., Bell T.A., Welsh C.E., Bonhomme F., Yu A.H., Nachman M.W., Pialek J., Tucker P., Boursot P. Subspecific origin and haplotype diversity in the laboratory mouse. Nat. Genet. 2011, 43:648-655.